Glucocorticoid Receptor 

 186 Products   186 Products   1696 Diseases   95004 News 


«12...300301302303304305306307308309310...10671068»
  • ||||||||||  hydrocortisone / Generic mfg.
    Trial initiation date:  Imaging CRF X NOP Interactions in CUD (clinicaltrials.gov) -  Jun 28, 2022   
    P1,  N=80, Recruiting, 
    Initiation date: Sep 2021 --> Jun 2019
  • ||||||||||  Agamree (vamorolone) / Santhera
    Enrollment open:  A Study to Assess Vamorolone in Becker Muscular Dystrophy (BMD) (clinicaltrials.gov) -  Jun 28, 2022   
    P2,  N=39, Recruiting, 
    Trial completion date: Sep 2023 --> Apr 2024 | Trial primary completion date: Dec 2022 --> Jul 2023 Not yet recruiting --> Recruiting
  • ||||||||||  bortezomib / Generic mfg., dexamethasone / Generic mfg., pomalidomide / Generic mfg.
    New P2 trial:  PVd Versus Vd in NDMM Patients With RI (clinicaltrials.gov) -  Jun 26, 2022   
    P2,  N=79, Not yet recruiting, 
  • ||||||||||  Trelegy Ellipta (fluticasone furoate/umeclidinium bromide/vilanterol) / GSK, Innoviva, Theravance Biopharma
    CAPTAIN study: Effects of baseline IgE levels on triple therapy response in inadequately controlled asthma (Ponce Foyer) -  Jun 26, 2022 - Abstract #EAC2022EAC_15;    
    P3
    Effects of adding UMEC and/or increasing FF dose according to IgE levels were generally consistent with the overall population. Although eosinophils and IgE levels are associated with type-2 inflammation, their influence on treatment response differs; unlike eosinophils, baseline IgE levels do not appear to predict treatment response.
  • ||||||||||  Trelegy Ellipta (fluticasone furoate/umeclidinium bromide/vilanterol) / GSK, Innoviva, Theravance Biopharma
    CAPTAIN: Relationship between FEV1 reversibility at screening as a continuous variable and treatment response (Ponce Foyer) -  Jun 26, 2022 - Abstract #EAC2022EAC_13;    
    P3
    Improvements in lung function were largely independent of FEV1 reversibility at screening, with greater improvements observed following UMEC addition. Increasing FF dose led to a reduction in moderate/severe exacerbation rates independently of FEV1 reversibility at screening, whereas adding UMEC had a minimal effect.
  • ||||||||||  fluticasone / Generic mfg.
    Rationale and Design for Randomized, Double-Blind, EDS-Placebo–Controlled Trials of EDS-FLU in Chronic Rhinosinusitis (Ponce Foyer) -  Jun 26, 2022 - Abstract #EAC2022EAC_1;    
    In the absence of a standardized drug development pathway for CRS, a panel of experts developed a novel study design for the exhalation delivery system with fluticasone (EDS-FLU) that meets the criteria set forth in prior FDA draft guidance and is feasible to conduct and generalizable to the CRS population... Thoughtful preparation, input from FDA, and applying an iterative process yielded a novel study design for testing CRS therapies.
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  Human Trabecular Meshwork (HTM) Cells Treated with TGF-β2 or Dexamethasone Respond to Compression Stress in Different Manners. (Pubmed Central) -  Jun 25, 2022   
    However, such compression stresses for 30 min toward TGF-β2- or DEX-treated 3D HTM spheroids induced downregulation of most of those of inflammatory cytokines and ER stress-related factors in addition to upregulation of COL1 and downregulation of FN. The findings presented herein indicate that (1) OXPHOS of the HTM cells was decreased or increased by TGF-β2 or DEX stimulation or ROCK2 inhibition, and (2) mechanical compression stresses toward 3D HTM spheroids may replicate acute, subacute, and chronic HTM models affected by elevated intraocular pressures.
  • ||||||||||  dexamethasone / Generic mfg.
    Biomarker, Journal:  Transcriptional Biomarkers and Immunohistochemistry for Detection of Illicit Dexamethasone Administration in Veal Calves. (Pubmed Central) -  Jun 25, 2022   
    According to the conventional univariate approach, a not-significant reduction in type I fibres was recorded in the DEX-treated group, and only 12 out of 28 targeted genes maintained their expected differential expression, confirming the technical limitations of a quantitative analysis on FFPE samples. However, the multivariate models developed highlighted the possibility to establish complementary screening strategies, particularly when based on transcriptional biomarkers characterised by low expression profiles.
  • ||||||||||  ivermectin oral / Generic mfg.
    Biomarker, Review, Journal:  Will the Use of Pharmacogenetics Improve Treatment Efficiency in COVID-19? (Pubmed Central) -  Jun 25, 2022   
    There are many types of available COVID-19 therapies, including antiviral agents (remdesivir, lopinavir/ritonavir, oseltamivir), antibiotics (azithromycin), antiparasitics (chloroquine, hydroxychloroquine, ivermectin), and corticosteroids (dexamethasone)...The knowledge of pharmacogenetic issues, which translate into variability in drug conversion from prodrug into drug, metabolism as well as transport, could help to predict treatment efficiency and the occurrence of adverse effects in patients. However, many drugs used for the treatment of COVID-19 have not undergone pharmacogenetic studies, perhaps as a result of the lack of time.
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  Biomimetic Metal-Organic Frameworks as Targeted Vehicles to Enhance Osteogenesis. (Pubmed Central) -  Jun 24, 2022   
    Herein, a stem cell membrane (SCM)-wrapped dexamethasone (DEX)-loaded zeolitic imidazolate framework-8 (ZIF-8) is constructed, which integrates the synthetic nanomaterials with native plasma membrane, to achieve efficient DEX delivery and DEX-mediated bone repair...In the bone defect model, the administrated DEX@ZIF-8-SCM exerts excellent biocompatibility and effectively promotes bone regeneration. Overall, the SCM-derived biomimetic nanoplatform achieves targeted delivery, excellent biosafety, and enhanced osteogenic differentiation and bone repair, which provides a new and valid strategy for treating various tissue injuries.
  • ||||||||||  Carafate (sucralfate) / AbbVie
    Is Opioid Use in the Management of Stage III Non-Small Cell Lung Cancer Patients Necessary? (Exhibit Hall - Hall B) -  Jun 24, 2022 - Abstract #IASLCWCLC2022IASLC_WCLC_1808;    
    Most patients with unresectable stage III NSCLC undergoing chemoradiation were able to manage their pain without the use of opioids by relying on adjuncts such as NSAIDs, PPIs, and steroids. Future studies should examine pain management regimens in a randomized control trial to better assess the efficacy of non-opioid pain medications.Observed pain regimens in Stage III NSCLC patients undergoing definitive chemoradiation.
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
    NIVIPI-BRAIN, A Phase II Study of Nivolumab plus Ipilimumab Combined with Chemotherapy for Patients with NSCLC and Synchronous Brain Metastases (Exhibit Hall - Hall B) -  Jun 24, 2022 - Abstract #IASLCWCLC2022IASLC_WCLC_1361;    
    Patients with multiple, untreated and measurable BM, adequate performance status and organ function, without EGFR, ALK or ROS1 genomic alterations, treatment naïve and without contraindication to receive immunotherapy were assigned to two cohorts: (A) Asymptomatic BM not requiring systemic corticosteroids (n=44); (B) BM causing neurologic signs and symptoms controlled with doses of corticosteroids equivalent to ≤ 4mg/d of dexamethasone with good performance status (n=27). Clinical trial in progress
  • ||||||||||  Lorbrena (lorlatinib) / Pfizer, NVL-655 / Nuvalent
    Preclinical Activity of NVL-655 in a Patient-Derived NSCLC Model with Lorlatinib-Resistant ALK G1202R/T1151M Mutation (Exhibit Hall - Hall B) -  Jun 24, 2022 - Abstract #IASLCWCLC2022IASLC_WCLC_1002;    
    The potent preclinical activity of NVL-655 suggests potential clinical utility for ALK-positive patients, including those with resistant compound mutations. The MR448re PDC and xenograft are valuable additions to the ALK therapeutic research landscape where there is limited availability of patient-derived models with lorlatinib-resistant ALK compound mutations.
  • ||||||||||  methylprednisolone oral / Generic mfg.
    Journal, IO biomarker:  The Effect of TLR9, MyD88, and NF-κB p65 in Systemic Lupus Erythematosus. (Pubmed Central) -  Jun 24, 2022   
    All SLE patients were treated with methylprednisolone tablets...MyD88 and NF-κB p65 were positively correlated with SLEDAI. Compared with a healthy status, SLE induces an increase in TLR9, MyD88, NF-κB p65, IL-6, and TNF-α levels, and the activation of the TLR9-MyD88-NF-κB p65 signal path was associated with the pathogenesis of SLE.
  • ||||||||||  Trial completion date, Trial primary completion date:  A Study in Adults With Untreated Acute Lymphoblastic Leukemia (clinicaltrials.gov) -  Jun 24, 2022   
    P2,  N=100, Active, not recruiting, 
    Further research is necessary to translate these findings into clinical practice. Trial completion date: Jul 2022 --> Jul 2023 | Trial primary completion date: Jan 2022 --> Jan 2023
  • ||||||||||  methylprednisolone sodium succinate / Generic mfg.
    Trial completion date, Trial primary completion date:  Methylprednisolone Injections Treating Birch Pollen Induced Allergic Rhinitis. (clinicaltrials.gov) -  Jun 24, 2022   
    P4,  N=44, Active, not recruiting, 
    Trial completion date: Jul 2022 --> Jul 2023 | Trial primary completion date: Jan 2022 --> Jan 2023 Trial completion date: Aug 2021 --> May 2023 | Trial primary completion date: May 2019 --> Jun 2022